Advertisement

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement

Sep

20

Today In Oncology

Contemporary Management of Chronic Myeloid Leukemia, According to Hagop M. Kantarjian, MD, FASCO

Adjuvant Chemoradiotherapy vs Radiotherapy for High-Risk Endometrial Cancer: 10-Year PORTEC-3 Outcomes

Proton Craniospinal Irradiation for Leptomeningeal Metastasis in Lung or Breast Cancer

Overall Survival After Hormonal Therapy vs Hysterectomy in Early Endometrial Cancer

Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types

Advertisement

© 2025 HSP News Service, L.L.C.